Clinical trial
Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal…
NCT00122330 · Alexion Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00122330 |
|---|---|
| Title | Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients |
| Official title | Randomized, Double-Blind, and Placebo-Controlled Study Using Eculizumab in Transfusion Dependent PNH Patients |
| Lead sponsor | Alexion Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hemoglobinuria, Paroxysmal |
| Intervention type | Drug |
| Interventions | eculizumab |
| Enrollment | 75 |
| Start date | Oct 1, 2004 |
| Completion | Jan 1, 2006 |
| First posted | Jul 22, 2005 |
| Last update posted | Dec 4, 2006 |
| Countries | Australia, Belgium, Canada, France, Germany, Ireland, Italy, Netherlands, Sweden, Switzerland, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: